Group 1 - The company is currently conducting data analysis for the Phase II clinical trial of Fluorofenone [1] - Investors are advised to pay attention to the relevant announcements disclosed by the company regarding the clinical trial report [1]

天眼查商业履历信息显示，海南海药股份有限公司，成立于1992年，位于海口市，是一家以从事医药制 造业为主的企业。企业注册资本129736.5126万人民币，实缴资本129736.5126万人民币。公司法定代表 人为王建平。 通过天眼查大数据分析，海南海药股份有限公司共对外投资了35家企业，参与招投标项目15次，知识产 权方面有商标信息18条，专利信息5条，此外企业还拥有行政许可82个。 来源：金融界 金融界消息 截至2025年8月12日收盘，海南海药（000566）报收于6.28元，下跌0.95%，换手率2.9%， 成交量33.83万手，成交金额2.13亿元。 资金流向方面，今日主力资金净流出3134.57万元，占比成交额14.71%。其中，超大单净流出2118.89万 元、占成交额9.94%，大单净流出1015.68万元、占成交额4.77%，中单净流出流入383.06万元、占成交 额1.8%，小单净流入2751.51万元、占成交额12.91%。 海南海药最新一期业绩显示，截至2025一季报，公司营业总收入2.07亿元、同比减少43.09%，归属净利 润6836.55万元，同比减少331.54%，扣非净利润7 ...

Group 1 - As of August 8, 2025, Hainan Haiyao's stock price is 6.32 yuan, with an increase of 0.01 yuan, representing a rise of 0.16% from the previous trading day [1] - The trading volume on that day was 263,462 hands, with a total transaction amount of 166 million yuan [1] - The company's current total market capitalization is 8.199 billion yuan, and the circulating market capitalization is 7.369 billion yuan [1] Group 2 - On August 8, the net inflow of main funds was 4.2386 million yuan, but over the past five days, the overall trend has shown a net outflow of 75.777 million yuan [1]

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024 [1] - The average annual salary of CFOs in the chemical preparation sector of A-shares is 1.0448 million yuan [1] - The age distribution of CFOs shows that those aged 40-50 constitute 47% of the market, while those aged 60 and above account for only 4% [1] Group 2 - The top three highest-paid CFOs are Lü Hongbin from Dize Pharmaceutical with 4.2101 million yuan, Si Yanzha from Lizhu Group with 3.904 million yuan, and Lai Dequ from Kelun Pharmaceutical with 3 million yuan [2] - The largest salary decrease was observed for Xu Rongyi from Hainan Haiyao, with a year-on-year decline of 48.66% [2] - The highest salary increase was recorded for Wang Lin from Ailis, with a year-on-year increase of 104.6% [2]

责任编辑：公司观察 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有87家上市化学制剂公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到47%；60岁以上的CFO占比 为4%；50岁-60岁的CFO群体占比为39%；40岁及以下CFO群体占比为10%。其中，目前仍任职的最年 轻的上市公司CFO年龄33岁，为北陆药业的曾妮。 从CFO的学历分布看，拥有大专、本科、硕士、博士学历的CFO占比分别为9%、52%、38%、1%。其 中，获得博士学历的CFO仅一人，为恒瑞医药的刘健俊。 从薪酬分布看，A股化学制剂公司CFO年薪平均值为104.48万元。经统计，处于50万以下、50万-100 万、100万-20 ...

Company Overview - Hainan Haiyao's stock price closed at 6.50 yuan on August 5, down 0.06 yuan, a decrease of 0.91% from the previous trading day [1] - The trading volume on that day was 413,556 hands, with a transaction amount of 269 million yuan [1] - The stock price fluctuated between 6.44 yuan and 6.60 yuan, with a volatility of 2.44% [1] Business Operations - Hainan Haiyao operates in the pharmaceutical manufacturing industry, focusing on drug research, production, and sales [1] - The company's product line includes antibiotics, anti-tumor drugs, and cardiovascular medications across various therapeutic areas [1] - The company is registered in Haikou City, Hainan Province [1] Clinical Development - On August 5, the company announced on an interactive platform that its innovative drug, Fluorofenone, requires Phase III clinical trials, with the specific launch date to be determined based on the progress of these trials [1] Shareholder Information - As of July 31, the total number of shareholders was 87,580, an increase of 17,700 from July 20 [1] - The number of shares held by the Shenzhen Stock Connect remained at 7.7945 million shares, accounting for 0.60% of the circulating share capital [1] Capital Flow - On August 5, the net outflow of main funds was 29.6253 million yuan, representing 0.39% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 59.3909 million yuan, accounting for 0.78% of the circulating market value [1]

证券日报网讯海南海药（000566）8月5日在互动平台回答投资者提问时表示，截至2025年7月31日，公 司股东户数为87580户。 ...

Group 1 - The company responded to an investor inquiry regarding the number of shareholders as of July 31, 2025, stating that the number is 87,580 [1]

资金流向方面，今日主力资金净流出1499.11万元，占比成交额2.88%。其中，超大单净流出726.06万 元、占成交额1.39%，大单净流出773.05万元、占成交额1.48%，中单净流出流出834.58万元、占成交额 1.6%，小单净流入2333.69万元、占成交额4.48%。 海南海药最新一期业绩显示，截至2025一季报，公司营业总收入2.07亿元、同比减少43.09%，归属净利 润6836.55万元，同比减少331.54%，扣非净利润7902.87万元，同比减少288.68%，流动比率0.318、速动 比率0.230、资产负债率91.51%。 金融界消息 截至2025年7月29日收盘，海南海药（000566）报收于6.66元，下跌0.75%，换手率6.72%， 成交量78.40万手，成交金额5.21亿元。 通过天眼查大数据分析，海南海药股份有限公司共对外投资了35家企业，参与招投标项目15次，知识产 权方面有商标信息18条，专利信息5条，此外企业还拥有行政许可82个。 来源：金融界 天眼查商业履历信息显示，海南海药股份有限公司，成立于1992年，位于海口市，是一家以从事医药制 造业为主的企业。企业注册 ...

Core Viewpoint - Hainan Haiyao has been awarded the "ESG Carbon Path Practitioner Award" for its outstanding practices in environmental, social, and governance (ESG) areas, highlighting its commitment to sustainable development and social responsibility [1][4]. Group 1: Environmental Practices - The company implements an EHS strategic goal, focusing on clean production, resource conservation, and green low-carbon transformation, significantly reducing energy consumption and pollutant emissions [4]. - During the reporting period, Hainan Haiyao did not experience any major environmental pollution incidents, demonstrating effective energy-saving and emission-reduction results [4]. - The company is continuously pursuing circular transformation to achieve carbon neutrality [4]. Group 2: Social Responsibility - Hainan Haiyao emphasizes employee health and safety, achieving zero work-related injuries and fatalities for three consecutive years, maintaining a million-hour death rate of 0% [4]. - The company actively conducts occupational disease health checks covering nearly a thousand employees and provides professional medical services through its medical sector [4]. Group 3: Governance Structure - Hainan Haiyao has established a scientific compliance system, revising its compliance management measures to enhance decision-making transparency and effectively address grievances [4]. - The company has introduced 24 new anti-corruption measures to ensure transparency in power supervision and safeguard business integrity [4]. Group 4: Future Outlook - The company plans to continue implementing its "14th Five-Year" strategic plan, focusing on high-quality development, deepening green low-carbon transformation, and innovative research and development [5]. - Hainan Haiyao aims to accelerate its position as a leading domestic manufacturer of active pharmaceutical ingredients and intermediates while strengthening its ESG integration practices [5]. - The new journey of Hainan Haiyao will further consolidate its ESG leadership and create greater environmental and social value [5].